Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors

You may be eligible if

• Histologically confirmed HER2/neu-overexpressing (2+ or 3+) malignancy by any standardized assay (fluorescence in-situ hybridization allowed)
• Measurable or evaluable disease
• Failed standard curative therapy
• No brain or CNS metastasis
• Hormone receptor status:
• * Not specified
• Male or female
• Performance status - Karnofsky 70-100%
• At least 6 months
• Absolute neutrophil count at least 1,500/mm\^3
• Hemoglobin at least 8 g/dL (transfusion or epoetin alfa allowed)
• Platelet count at least 100,000/mm\^3
• Bilirubin no greater than 1.5 times upper limit of normal (ULN)
• AST and ALT no greater than 3.0 times ULN
• Hepatitis B surface antigen negative
• Creatinine no greater than 1.5 times ULN
• Calcium no greater than 11 mg/dL (calcium-lowering agents allowed)
• No active or unstable cardiovascular disease
• No cardiac disease requiring drug or device intervention
• No coronary artery disease
• No congestive heart failure
• Cardiac ejection fraction normal by echocardiogram or MUGA scan
• No significant peripheral neuropathy
• No significant CNS disease
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• HIV negative
• No serious concurrent infection requiring IV antibiotic therapy
• No clinically significant autoimmune disease (e.g., rheumatoid arthritis)
• No clinically significant gastrointestinal bleeding
• No uncontrolled peptic ulcer disease
• No inflammatory bowel disease
• No other major illness that would preclude study participation
• No other concurrent malignancy except non-melanoma skin cancer or carcinoma in situ of the cervix
• No prior interleukin-12
• No prior trastuzumab (Herceptin®)
• At least 3 weeks since prior chemotherapy
• At least 3 weeks since prior hormonal therapy
• No concurrent systemic corticosteroids
• At least 3 weeks since prior radiotherapy
• At least 3 weeks since prior surgery
• At least 3 weeks since prior investigational drug